Finance Essay Sample

Focus on anti- HIV drugs- Gilead Sciences

Aggressive focus on HIV drugs
Gilead Sciences has always been known for its aggressive focus on production of efficient anti-HIV drugs. One of the blockbuster achievements of the company in this regard was achieved in collaboration with Johnson and Johnson through the discovery of Eviplera, an effective medicine that blocks the spread of the human immunodeficiency virus. The drug was approved in Europe and USA in the year 2011.
The very next expansion to the HIV drug portfolio was achieved in 2012 when the company won the approval for its new drug, Stribild, a daily pill that treats HIV Type 1 in adults who are beginning treatment. At present, Stribild is the second most leading medicine prescription for HIV patients, behind another Gilead drug, Atripla.
Moreover, the company during November, 2014, has filed a new drug application with USFDA for an investigational drug for the treatment of HIV-1 infection in the adults with once-daily single tablet regiment. If approved, the drug will be the first single tablet regiment drug of the company. In addition, this will likely bring a revolution in the pharmaceutical industry.
Gilead Sciences offers multiple HV treatment drugs in the US market that accounts for 72.80% of the total revenue of the company, generating $8.1 billion in sales volume with forecasted figures standing at $9.06 billion for 2014.

Works Cited

Gliead Sciences. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV. n.d. 21 February 2015 <http://gilead.com/news/press-releases/2014/11/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-tenofovir-alafenamide-tafbased-single-tablet-regimen-for-hiv>.
Ishmael, Hannah. Gilead Sciences, Inc (GILD): More Of An HCV-Focused Company Now? 23 January 2015. 21 February 2015 <http://www.bidnessetc.com/33123-gilead-sciences-inc-more-of-an-hcvfocused-company-now/>.
Lee, Stephanie. Gilead seeks approval for new HIV pill. 6 November 2014. 21 February 2015 <http://www.sfgate.com/business/article/Gilead-seeks-approval-for-new-HIV-pill-5876766.php>.